Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Regina Yavel

Dermatology Commack, NY Medical Doctor

NPI 1871529016 CMS profile 311130

353 Veterans Memorial Hwy, Commack, NY 11725

Open in the dashboard

General payments

$3,765

143 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$158,220 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Regina Yavel of Commack, NY is reported in the CMS Open Payments database as having received $3,765 across 143 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $158,220 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 58th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $644 28
2024 General $691 34
2023 General $941 30
2022 General $473 20
2021 General $252 8
2020 General $75 4
2019 General $690 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Regina Yavel
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Regina Yavel were reported at $644. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Regina Yavel Dermatology median Middle half National median
2019 $690 $454 $129–$1,240 $163
2020 $75 $235 $81–$756 $114
2021 $252 $377 $108–$1,108 $132
2022 $473 $514 $143–$1,391 $149
2023 $941 $607 $159–$1,674 $160
2024 $691 $751 $204–$1,903 $164
2025 $644 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Biotech, Inc. $968 42 payments
  2. AbbVie, Inc. $664 23 payments
  3. Genzyme Corporation $560 21 payments
  4. Incyte Corporation $407 14 payments
  5. LEO Pharma Inc. $275 12 payments
  6. Genentech USA, Inc. $127 1 payment
  7. Janssen Scientific Affairs, LLC $125 1 payment
  8. Sun Pharmaceutical Industries Inc. $107 4 payments
  9. Regeneron Healthcare Solutions, Inc. $97 4 payments
  10. Lilly USA, LLC $89 4 payments
  11. Other $346 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,500 140 payments
  2. Education $265 3 payments
Products named General payments · program years 2019–2025
  1. TREMFYA $1,016 38 payments
  2. DUPIXENT $820 28 payments
  3. SKYRIZI Immunology $428 13 payments
  4. OPZELURA $407 14 payments
  5. STELARA $249 16 payments
  6. SIMPONI ARIA $224 15 payments
  7. SIMPONI $224 15 payments
  8. SKYRIZI Immunology $186 7 payments
  9. ENSTILAR $136 7 payments
  10. Erivedge $127 1 payment
  11. Other $876 41 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

301

Median for Dermatology: 534

Drug cost

$4,587

Median for Dermatology: $67,151

Branded share of claims

11.6%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ketoconazole Generic 79 $1,271
Fluocinonide Generic 15 $710
Clobetasol Propionate Generic 18 $629
Doxycycline Hyclate Generic 26 $499
Ciclopirox Ciclopirox Olamine Brand 24 $431
Mupirocin Generic 57 $333
Econazole Nitrate Generic 11 $174
Nystatin Generic 12 $167
Minoxidil Generic 23 $158
Triamcinolone Acetonide Generic 14 $112

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$156,258

Of which drugs: $11,883

Medicare patients

300

Average age 75

Services billed

1,894

197 women, 103 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 48%
Ischemic heart disease 29%
Osteoporosis 25%
Diabetes 24%
Cancer 21%
Atrial fibrillation 16%
Chronic kidney disease 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 12 22 $16

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $226
$226 — —
DUPIXENT
  • GENZYME CORPORATION $121
  • Regeneron Healthcare Solutions, Inc. $24
$145 — —
SKYRIZI
  • AbbVie, Inc. $69
$69 — —
OPZELURA
  • Incyte Corporation $63
$63 — —
SIMPONI
  • Janssen Biotech, Inc. $37
$37 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

143 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record